IL-5/IL-13 bispecific antibody (GlaxoSmithKline)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-5/IL-13 bispecific antibody (GlaxoSmithKline)

Drug Alias Nameanti-IL5/13 bispecific dAb-mAb (GSK)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionInterleukin-5 receptors inhibitorsInterleukin 13 receptor inhibitors

TargetsInterleukin 13 receptorInterleukin-5 receptors

Therapy Area/IndicationsAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsAsthma

Other Information

ATC CodeN/A